AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02653066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HealtheRx++
Description: Participant receives $5 bill when they returned signed PRR consent form.
Study NCT03343509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Oral
Description: Oral Metronidazole
Study NCT03343509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Ointment
Description: Metronidazole Ointment
Study NCT03343509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo Tablet
Study NCT03343509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Ointment
Description: Placebo Ointment
Study NCT03751098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tropicamide/Phenylephrine ophthalmic solution (TR/PE)
Description: Tropicamide 1%/phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
Study NCT00889785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (disease management program)
Description: The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
Study NCT00889785 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Will receive usual care and monthly phone calls as an active control.
Study NCT00323609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: Vertebroplasty involves placement of a needle into the vertebral body. Cement is injected into the vertebral body.
Study NCT00323609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphoplasty
Description: Balloon Kyphoplasty involves two inflatable bone tamps placed into the vertebral body in the spine. After the tamps are removed, the void is filled with viscous bone cement.
Study NCT01058382 — intervention group
Intervention type: DRUG
Intervention: Progesterone Vaginal Suppositories
Description: Progesterone Vaginal Suppositories 200 mg three times daily for 10 weeks following embryo transfer
Study NCT01058382 — intervention group
Intervention type: DRUG
Intervention: Intramuscular Progesterone-in-Oil
Description: Progesterone-in-Oil 50 mg IM once daily for 10 weeks following embryo transfer
Study NCT03751098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Eyewash administered with the Optejet microdose dispenser
Study NCT03076671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: Palliative care training for community neurologists and use of telemedicine for team-based support of patients
Study NCT03696212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grapiprant and pembrolizumab
Description: Participants will be administered 21-day cycles of oral grapiprant in combination with IV pembrolizumab
Study NCT02570308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCgp100
Description: Bispecific soluble HLA-A2 restricted gp100-specific T-cell receptor fused to anti-CD3
Study NCT01469988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone
Description: Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.
Study NCT01469988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.
Study NCT02953197 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG-PET guided radiation dose escalation
Description: Selective dose escalation
Study NCT03066440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in normal saline for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
Study NCT03066440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringers
Description: All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in lactated ringer's solution for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
Study NCT03078842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc tablets, 20 mg per day
Description: Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 20 mg of zinc
Study NCT03078842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc tablets, 10 mg per day
Description: Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 10 mg of zinc
Study NCT03078842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc tablets, 5 mg per day
Description: Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 5 mg of zinc
Study NCT03385876 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genomic sequencing and molecular diagnostic results, if any
Description: Samples will be stored in the pediatric genomic biorepository. A subset of samples will undergo genetic/genomic analysis.
Study NCT03496532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biphasic stimulation
Description: Fixed 70Hz symmetrical biphasic pulses
Study NCT00744653 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electrochemotherapy
Description: Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz. Drug used is Bleomycin.
Study NCT03334123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional training and cycling
Description: First 8 weeks: patients will perform 20 minutes of functional training before their dialysis procedure. The exercise program will be run by kinesiologists, who will also teach patients how to perform exercises on their own at home. During intradialysis cycling 3 times weekly participants will cycle on adapted ergometer. Participants will start with 10 - 15 minutes of cycling and then gradually increase time and intensity up to 45 minutes of duration.~Second phase of 8 weeks: participants will no longer perform functional training before dialysis but will be motivated, monitored and advised to perform functional exercise at home on non-dialysis days for 20-30 minutes and continue with cycling sessions during the dialysis procedures three times weekly.
Study NCT03334123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycling
Description: First 8 weeks: cycling on an adapted ergometer during dialysis; starting with 10 - 15 minutes of cycling and then gradually increasing time and intensity up to 45 minutes of duration.~Second 8 weeks: continue with cycling at the target duration and intensity during dialysis.
Study NCT01408160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT01408160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins
Description: Given IV
Study NCT01408160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01408160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT04207723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation
Description: Three (3) sessions per week per twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual.
Study NCT04207723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: paroxetine 20 mg / day taken in the morning hours, per 12 weeks.
Study NCT04207723 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Paroxetine
Description: paroxetine 20 mg / day taken in the morning hours, per 12 weeks.
Study NCT00845572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consta Club
Description: Biweekly group for patients receiving Risperdal Consta injections. Each 45 minute group includes socialization time, goal-setting, illness and medication education, and refreshments.
Study NCT03516331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL176 & FDL169 coadministration
Description: CFTR corrector and potentiator
Study NCT03496532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard stimulation
Description: Fixed 70Hz pseudo-monophasic pulses
Study NCT03496532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uniform distribution
Description: Uniform distribution 70Hz Biphasic pulses
Study NCT03496532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Poisson distribution
Description: Poisson distribution 70Hz Biphasic pulses
Study NCT03496532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recordings of LFP oscillations
Description: Two minutes of recordings of LFP oscillations will be performed from the contacts of the implanted electrode.~Recordings of the depth of anaesthesia (BIS) all along the measurements performed under general anaesthesia.The correlation between the depth of anaesthesia and the cerebral oscillations recorded at the site of subthalamic nucleus will be studied.
Study NCT03708861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD)
Description: Phase 1: switch from tenofovir disoproxil fumarate/emtricitabine (200/245 mg QD)+ atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD).~Phase 2: switch from maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (200 /100 mg QD)
Study NCT03777787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Denatonium Benzoate
Description: A single intragastric administration of denatonium benzoate (1 µmol/kg)
Study NCT03777787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: A single intragastric administration of water
Study NCT03686800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rivelin® plain patches
Description: The comfort and adherence of Rivelin® plain patches in Vulva Lichen Sclerosus patients
Study NCT01447329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ear Acupuncture
Description: Ear acupuncture utilizes up to 10 needles. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The subject will receive five needles intra-operatively on each ear.
Study NCT01447329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Treatment
Study NCT03367286 — intervention group
Intervention type: OTHER
Intervention: inspection mode
Description: different inspection modes：Computed Tomography Perfusion (CTP) or Magnetic Resonance Perfusion (MRP)
Study NCT01405885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3605
Description: 0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
Study NCT01405885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3609
Description: 0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
Study NCT01405885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3401
Description: 0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
Study NCT01405885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3609
Description: 0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
Study NCT01405885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3605 AND INO-3609
Description: 0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
Study NCT01405885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3510
Description: 0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
Study NCT01405885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3609
Description: 0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
Study NCT01405885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3609
Description: 0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
Study NCT01405885 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal Influenza vaccine
Description: 0.5ml of vaccine delivered IM
Study NCT01405885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3609
Description: 1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
Study NCT00240084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide (Natrecor(TM))
Description: administration of IV nesiritide
Study NCT03493698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam
Study NCT00974857 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BCM
Description: Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight at least once a month before a dialysis session.
Study NCT00974857 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
Study NCT03493698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir
Description: Inarigivir
Study NCT04829838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous levetireacetam
Description: phenytoin is considered as control drug in the study
Study NCT03198988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smART Feeding Tube System
Description: Replacing generic feeding tube with smART Feeding Tube System.
Study NCT03557437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT03557437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT03557437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin, Metronidazole
Description: Antibiotics for H. pylori eradication
Study NCT03557437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin, Metronidazole
Description: Antibiotics for H. pylori eradication
Study NCT03557437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT01995123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy
Description: Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.
Study NCT01995123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Smoking Education
Description: Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.
Study NCT04341818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training and Vitamin D monthly
Description: For 4 wks 50.000 IU vitamin D is given as a monthly dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
Study NCT03296176 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: blood sample for metabolome analyse
Study NCT04341818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training and Vitamin D daily
Description: For 4 wks 800 IU vitamin D is given as a daily dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
Study NCT04341818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training and no Vitamin D
Description: For 4 wks no vitamin D is administered, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the also no vitamin D is given. Over the whole study period participants get 400 mg calcium/day.
Study NCT03876756 — intervention group
Intervention type: OTHER
Intervention: postpartum acute urinary retention
Description: Collection of risk factors
Study NCT03876756 — intervention group
Intervention type: OTHER
Intervention: no postpartum acute urinary retention
Description: Collection of risk factors
Study NCT04261296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: In this treatment, depending on the thickness of the adipose tissue under the skin, 13 mm, 25 mm or 30 mm long; 0.20 mm thick acupuncture needle is used
Study NCT04261296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balneotherapy
Description: This treatment method; An alert-fit performed in a certain time interval and in a cure style by using the methods and doses of hot mineral waters, gases and peloids (sludge) from natural underground, determined in detail, repeatedly in series as bath, drinking and inhalation treatments. treatment can be defined as. There are studies showing that the effect of balneotherapy is mechanical, thermal, chemical, anti-inflammatory and immunological.
Study NCT04261296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling +balneotherapy
Description: Both of these methods will be applied to patients in the third group.
Study NCT01248312 — intervention group
Intervention type: DEVICE
Intervention: Sentec monitoring device
Description: Sentec monitor applied transcutaneously to forehead
Study NCT01248312 — intervention group
Intervention type: DEVICE
Intervention: sentec monitor
Description: transcutaneous monitoring
Study NCT04157634 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prognostication model
Description: In a prospective cohort of children hospitalized in a PICU, developement a model based on biomarkers, HRV, and a computerized classifier output, to predict long-term neurological outcome after a moderate or severe TBI in children aged 0 to 18 years.
Study NCT00447187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX201
Description: LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded.
Study NCT00447187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
Study NCT01995123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Smoking Cessation Therapy
Description: Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.
Study NCT01995123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Smoking Cessation Therapy
Description: Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.
Study NCT03380962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab
Description: All patients will receive clazakizumab 25 mg subcutaneous injections (monthly) for a maximum of 18 injections.
Study NCT04458350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Promotions Group
Description: Digital promotions on the Fresh EBT app and Facebook will run for 13 weeks, advertising a SNAP fruit and vegetable incentive at farmers' markets in New England. The intervention will be applied to zip codes randomized to the intervention arm.
Study NCT00354874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: drug
Study NCT00354874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo